基于磁共振成像的前列腺癌筛查在致病性胚系突变携带者中的应用:前列腺癌遗传风险评估与筛查研究首轮筛查的中期结果
该研究纳入19个前列腺癌风险基因致病/可能致病胚系突变携带者男性(35-74岁),首轮筛查完成101例,采用年度PSA、直肠指检和每三年一次多参数MRI。MRI异常(PI-RADS≥3)对临床显著前列腺癌灵敏度100%(7/7),NPV 100%;单用PSA灵敏度57%(4/7),NPV 73%。决策曲线分析中,MRI筛查在所有阈值概率下净获益优于PSA筛查,每7.5例患者多检出1例癌症,同时避免更多不必要活检。
要点
- 在致病性胚系突变携带者中,基于MRI的筛查对临床显著前列腺癌的灵敏度为100%(7/7),NPV为100%。
- 单用PSA筛查的灵敏度为57%(4/7),NPV为73%。
- 决策曲线分析显示MRI筛查在所有阈值概率下净获益优于PSA筛查。
核心结论
- 在前列腺癌相关致病性胚系突变携带者中,疾病患病率高。
- 早期结果表明,基于MRI的筛查在PSA筛查基础上增强了临床显著疾病的早期检测。
研究设计与样本
- 研究招募了19个前列腺癌风险基因中任一基因致病/可能致病胚系变异携带者男性,年龄35-74岁,无前列腺癌病史。
- 入组参与者接受年度PSA、直肠指检和每三年一次多参数MRI筛查。
- 直肠指检异常、年龄调整PSA升高(35-49岁>1.5 ng/ml,50-54岁>2.0 ng/ml,55-74岁>3.0 ng/ml)或MRI可疑(PI-RADS≥3病变)者接受前列腺活检。
- 终点为任何前列腺癌和临床显著前列腺癌的诊断,并通过决策曲线分析比较替代筛查策略。
- 截至分析时,101例男性已完成首轮筛查。
主要发现
- 参与者中最大比例为BRCA2携带者(n=44),其次为BRCA1(n=35)和ATM(n=7)变异携带者。
- 21例接受了活检,检出9例癌症(其中7例为临床显著)。
- 对于临床显著前列腺癌的检测,MRI异常(PI-RADS≥3)的灵敏度为100%(7/7),NPV为100%。
- 单用PSA筛查的灵敏度为57%(4/7),NPV为73%。
- 决策曲线分析评估的6种筛查策略中,单用MRI筛查在所有阈值概率下净获益优于PSA筛查,每7.5例患者多检出1例癌症,同时在相同阈值概率下避免更多不必要活检。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The risk of early-onset and clinically aggressive prostate cancer is elevated in carriers of certain rare pathogenic germline mutations. The utility of augmenting traditional prostate-specific antigen (PSA)-based screening measures with multiparametric magnetic resonance imaging (MRI) in this population is not yet known. OBJECTIVE: To evaluate MRI-based screening in comparison with traditional PSA-based screening among individuals at an elevated genetic risk for prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: Male germline carriers of pathogenic/likely pathogenic variants in any of 19 prostate cancer risk genes between the ages of 35 and 74 yr with no prior history of prostate cancer were recruited. Intervention Enrolled participants underwent screening with annual PSA, digital rectal examination (DRE), and triennial multiparametric MRI. Individuals with abnormal DRE, elevated age-adjusted PSA (>1.5 ng/ml for 35-49 yr, >2.0 ng/ml for 50-54 yr, and >3.0 ng/ml for 55-74 yr), or suspicious multiparametric MRI (Prostate Imaging Reporting and Data System [PI-RADS] ≥3 lesion) were offered prostate biopsy. Outcome measurements and statistical analysis Endpoints were diagnosis of any and clinically significant prostate cancer, and alternative screening strategies were compared by a decision curve analysis. RESULTS AND LIMITATIONS: To date, 101 males have completed the first round of screening. The greatest proportion of participants are carriers of BRCA2 (n = 44), BRCA1 (n = 35), and ATM (n = 7) variants. Twenty-one have undergone biopsy, resulting in the detection of nine cases of cancer (seven clinically significant). For the detection of clinically significant prostate cancer, abnormal MRI (PI-RADS ≥3) demonstrated 100% sensitivity (7/7) with a negative predictive value (NPV) of 100%, whereas PSA-based screening alone had 57% (4/7) sensitivity with an NPV of 73%. Of six screening strategies evaluated in the decision curve analysis, MRI-based screening alone achieved superior net benefit at all threshold probabilities compared with PSA screening-detecting one additional cancer case per 7.5 patients, while avoiding more unnecessary biopsies at the same threshold probability. CONCLUSIONS: Disease prevalence is high among carriers of prostate cancer-associated pathogenic germline mutations. Early results suggest that MRI-based screening enhances early detection of clinically significant disease beyond PSA screening alone. PATIENT SUMMARY: In this study, we present the interim results from the PROGRESS prostate cancer screening trial. We found that in certain germline carriers of prostate cancer risk mutations, magnetic resonance imaging-based screening enhances detection of prostate cancer while reducing biopsies triggered, in comparison with traditional prostate-specific antigen screening strategies.
引用
- Amini AE, Hunter AE, Almashad A, et al. Magnetic Resonance Imaging-based Prostate Cancer Screening in Carriers of Pathogenic Germline Mutations: Interim Results from the Initial Screening Round of the Prostate Cancer Genetic Risk Evaluation and Screening Study. Eur Urol Oncol. 2024. PMID: 38453598. doi:10.1016/j.euo.2024.01.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。